Compare JPMorgan Chase & Co (JPM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs ResMed Inc. — how do they compare? JPMorgan Chase & Co trades at $345.22 (market cap $900.78B), while ResMed Inc. trades at $195.37 (market cap $28.81B). The key difference: JPMorgan Chase & Co is far larger — about 31.3× ResMed Inc.'s market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| JPM | RMD | |
|---|---|---|
Market Cap | $900.78B | $28.81B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $293.73 |
52-Week Low | $282.84 | $182.82 |
Dividend Yield | 1.77% | 1.21% |
Enterprise Value | — | $27.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $343.94, up 0.83% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.8B projected for 2026. The stock shows robust fundamentals with a P/E of 14.52 and net income margin of 33.4%, though cash flow trends indicate significant investing outflows.
Outlook remains positive with a consensus price target of $372.73, implying ~8.4% upside. Risks include geopolitical tensions affecting oil markets and cybersecurity threats highlighted in recent news. Institutional ownership is stable, supporting a moderate buy rating amid economic uncertainties discussed by CEO Jamie Dimon.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
